Welcome to the first Drug Pipeline Insights Report for 2024
Read the report for a review of:
- First approved drug for negative symptoms of schizophrenia
- First-in-class treatment for pulmonary arterial hypertension
- First FDA-approved drug for nonalcoholic steatohepatitis (NASH)
View the first Drug Pipeline Insights Report for 2024
Don't want to read the full report? View the summary
Related healthcare insights
Article
Helping make prescription drugs more affordable for plan sponsors and the members we serve is a universal focus.
Article
Prices for popular brand-name biologics drop up to 60% with generic-equivalent biosimilars.
Article
Explore innovations custom built for today’s specialty challenges.